NEW YORK — TomaLab said on Tuesday that it has signed an agreement with Natera to distribute three of that firm's cell-free DNA tests in Italy.
Under the terms of the deal, Busto Arsizio, Italy-based TomaLab will distribute Natera's Panorama noninvasive prenatal test, Signatera circulating tumor DNA test for cancer treatment monitoring and minimal residual disease assessment, and Prospera test for assessing transplant rejection.
Financial and other terms were not disclosed.
Earlier this year, San Carlos, California-based Natera reported a 62 percent jump in first quarter revenues amid growing demand for its tests.